NCT05291039View on ClinicalTrials.gov

Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.

NACompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

March 30, 2023

Study Completion Date

April 1, 2023

Conditions
Inflammatory Bowel Diseases
Interventions
DRUG

Infliximab

group 1 (n=20): patients will receive IFX

DRUG

Adalimumab

group 2 (n=20): patients will receive ADA

Trial Locations (1)

31527

Tropical Medicine department, Ain Shams University Hospitals., Cairo

All Listed Sponsors
lead

Rehab Werida

OTHER

NCT05291039 - Infliximab and Adalimumab in Inflammatory Bowel Disease Patients. | Biotech Hunter | Biotech Hunter